Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.

Animals Brain / metabolism Corpus Striatum / metabolism Disease Models, Animal Dopamine / metabolism Dyskinesia, Drug-Induced / drug therapy Levodopa / adverse effects Mass Spectrometry

Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
01 2021
Historique:
received: 01 09 2020
accepted: 10 11 2020
entrez: 1 2 2021
pubmed: 2 2 2021
medline: 16 4 2022
Statut: epublish

Résumé

l-DOPA treatment for Parkinson's disease frequently leads to dyskinesias, the pathophysiology of which is poorly understood. We used MALDI-MSI to map the distribution of l-DOPA and monoaminergic pathways in brains of dyskinetic and nondyskinetic primates. We report elevated levels of l-DOPA, and its metabolite 3-

Identifiants

DOI: 10.1126/sciadv.abe5948 PMID: 33523980 PMC: PMC7787486
pubmed: 33523980
pii: 7/2/eabe5948
doi: 10.1126/sciadv.abe5948
pmc: PMC7787486
pii:
doi:

Substances chimiques

Levodopa 46627O600J
Dopamine VTD58H1Z2X

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Références

Eur J Neurosci. 2005 Jul;22(1):283-7
pubmed: 16029219
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a009308
pubmed: 22393538
Neurochem Res. 2008 Mar;33(3):401-11
pubmed: 17713853
Neuroscience. 1982 Apr;7(4):951-75
pubmed: 7048127
Prog Neurobiol. 2011 Oct;95(2):163-212
pubmed: 21878363
Biol Psychiatry. 2016 Mar 1;79(5):345-353
pubmed: 25442003
Parkinsons Dis. 2015;2015:609428
pubmed: 25810948
Sci Transl Med. 2010 Apr 21;2(28):28ra28
pubmed: 20410529
Brain. 2007 Jul;130(Pt 7):1819-33
pubmed: 17452372
Ann Neurol. 2001 Mar;49(3):298-303
pubmed: 11261503
Neurosci Res. 2010 Sep;68(1):44-50
pubmed: 20542064
J Neurosci Methods. 2000 Mar 1;96(1):71-6
pubmed: 10704673
PLoS One. 2010 Aug 23;5(8):e12322
pubmed: 20808799
J Neurosci. 1987 Jan;7(1):279-90
pubmed: 2879896
Clin Neuropharmacol. 2003 May-Jun;26(3):156-63
pubmed: 12782919
Neuroimage. 1996 Oct;4(2):119-50
pubmed: 9345504
Neurochem Int. 1985;7(2):221-7
pubmed: 20492917
Neuroreport. 1999 Feb 25;10(3):631-4
pubmed: 10208602
J Neurol. 2002 Sep;249 Suppl 2:II19-24
pubmed: 12375059
Fluids Barriers CNS. 2012 Feb 08;9:4
pubmed: 22316420
Front Neural Circuits. 2017 Oct 09;11:72
pubmed: 29062274
J Clin Invest. 2014 Mar;124(3):1340-9
pubmed: 24531549
Front Neural Circuits. 2018 Jul 10;12:51
pubmed: 30042662
PLoS One. 2010 Nov 22;5(11):e14053
pubmed: 21124922
Mov Disord. 2012 Sep 15;27(11):1373-8
pubmed: 22976821
Cereb Cortex. 2015 Sep;25(9):2783-92
pubmed: 24770706
Int J Mol Sci. 2019 Dec 31;21(1):
pubmed: 31906250
Sci Rep. 2014 Jan 16;4:3730
pubmed: 24429495
Ann Neurol. 2010 Nov;68(5):619-28
pubmed: 20882603
Brain. 2015 Sep;138(Pt 9):2632-47
pubmed: 26117365
Neuroscience. 2009 Mar 3;159(1):16-20
pubmed: 19146929
Trends Pharmacol Sci. 2002 Jun;23(6):262-8
pubmed: 12084631
Sci Rep. 2017 Nov 22;7(1):16005
pubmed: 29167476
Neuron. 2014 Nov 19;84(4):697-707
pubmed: 25453841
Biol Pharm Bull. 2012;35(8):1244-8
pubmed: 22863920
Chem Rev. 2013 Apr 10;113(4):2309-42
pubmed: 23394164
J Clin Invest. 2012 Nov;122(11):3977-89
pubmed: 23041629
Mov Disord. 2013 Jul;28(8):1088-96
pubmed: 23389842
Sci Rep. 2017 May 24;7(1):2348
pubmed: 28539659
Nat Methods. 2019 Oct;16(10):1021-1028
pubmed: 31548706
Mov Disord. 2001 May;16(3):448-58
pubmed: 11391738
Neuropsychopharmacology. 2014 Jan;39(1):34-49
pubmed: 23966069
Brain Res. 1989 Jun 26;490(2):332-8
pubmed: 2765866
J Neurosci. 2001 Sep 1;21(17):6853-61
pubmed: 11517273
Exp Neurol. 2005 Sep;195(1):267-71
pubmed: 15925365
Prog Neurobiol. 1996 Aug;49(5):415-54
pubmed: 8895995
Brain. 2004 Dec;127(Pt 12):2747-54
pubmed: 15329355
Trends Pharmacol Sci. 2014 Jul;35(7):308-16
pubmed: 24878326
J Neurosci. 2006 Sep 13;26(37):9448-61
pubmed: 16971529
Neuropharmacology. 2016 Nov;110(Pt A):48-58
pubmed: 27424102
Neurology. 2006 Nov 14;67(9):1612-7
pubmed: 17101892
Brain Res. 1997 Aug 22;766(1-2):107-12
pubmed: 9359593
Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2517-26
pubmed: 25918399
Parkinsonism Relat Disord. 2015 Aug;21(8):871-6
pubmed: 26003410
Br J Pharmacol. 1986 Sep;89(1):229-34
pubmed: 3801773
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):18005-10
pubmed: 24127604
Neuroscience. 2010 Mar 17;166(2):355-8
pubmed: 20026252
Neurobiol Dis. 2010 Apr;38(1):136-43
pubmed: 20096781
Neurosci Lett. 2014 Apr 30;566:72-6
pubmed: 24572591
Prog Neurobiol. 2015 Sep;132:96-168
pubmed: 26209473
Synapse. 2016 Jun;70(6):231-9
pubmed: 26799359

Auteurs

Elva Fridjonsdottir (E)

Medical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0002-3779-3556

Reza Shariatgorji (R)

Medical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Science for Life Laboratory, National Resource for Mass Spectrometry Imaging, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0001-9484-0921

Anna Nilsson (A)

Medical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Science for Life Laboratory, National Resource for Mass Spectrometry Imaging, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0002-6183-6931

Theodosia Vallianatou (T)

Medical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0002-1477-7756

Luke R Odell (LR)

Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0001-7658-5103

Luke S Schembri (LS)

Medical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Science for Life Laboratory, National Resource for Mass Spectrometry Imaging, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0001-5588-1077

Per Svenningsson (P)

Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
ORCID: 0000-0001-6727-3802

Pierre-Olivier Fernagut (PO)

Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France.
Université de Poitiers, INSERM, U0-1084, Laboratoire de Neurosciences Expérimentales et Cliniques, Poitiers, France.
ORCID: 0000-0002-7737-5439

Alan R Crossman (AR)

University of Manchester, Manchester M13 9PL, UK.

Erwan Bezard (E)

Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France. erwan.bezard@u-bordeaux.fr per.andren@farmbio.uu.se.
CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France.
Motac Neuroscience, Manchester M15 6WE, UK.
ORCID: 0000-0002-0410-4638

Per E Andrén (PE)

Medical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden. erwan.bezard@u-bordeaux.fr per.andren@farmbio.uu.se.
Science for Life Laboratory, National Resource for Mass Spectrometry Imaging, Uppsala University, Uppsala, Sweden.
ORCID: 0000-0002-4062-7743

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Mass spectrometry imaging identifies...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Mass spectrometry imaging identifies...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Noyaux gris centraux › Corps strié › Mass spectrometry imaging identifies...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Mass spectrometry imaging identifies...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Catéchols › Catécholamines › Dopamine › Mass spectrometry imaging identifies...
questionsmedicales.fr › Troubles dus à des produits chimiques › Intoxication › Syndromes neurotoxiques › Dyskinésie due aux médicaments › Mass spectrometry imaging identifies...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés cycliques › Acides aminés aromatiques › Tyrosine › Dopa › Lévodopa › Mass spectrometry imaging identifies...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Spectrométrie de masse › Mass spectrometry imaging identifies...